CN104519879B - 使用类视色素激动剂治疗中性粒细胞减少症的方法 - Google Patents

使用类视色素激动剂治疗中性粒细胞减少症的方法 Download PDF

Info

Publication number
CN104519879B
CN104519879B CN201380041537.6A CN201380041537A CN104519879B CN 104519879 B CN104519879 B CN 104519879B CN 201380041537 A CN201380041537 A CN 201380041537A CN 104519879 B CN104519879 B CN 104519879B
Authority
CN
China
Prior art keywords
day
neutropenia
tamibarotene
composition
neutrophils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380041537.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104519879A (zh
Inventor
L·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Publication of CN104519879A publication Critical patent/CN104519879A/zh
Application granted granted Critical
Publication of CN104519879B publication Critical patent/CN104519879B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201380041537.6A 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法 Expired - Fee Related CN104519879B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US61/656,815 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (2)

Publication Number Publication Date
CN104519879A CN104519879A (zh) 2015-04-15
CN104519879B true CN104519879B (zh) 2018-10-02

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041537.6A Expired - Fee Related CN104519879B (zh) 2012-06-07 2013-06-07 使用类视色素激动剂治疗中性粒细胞减少症的方法

Country Status (13)

Country Link
US (1) US11116738B2 (enExample)
EP (1) EP2858636B1 (enExample)
JP (1) JP6295249B2 (enExample)
KR (1) KR102083046B1 (enExample)
CN (1) CN104519879B (enExample)
AU (1) AU2013270674B2 (enExample)
BR (1) BR112014030279A2 (enExample)
CA (1) CA2874850A1 (enExample)
ES (1) ES2691493T3 (enExample)
MX (1) MX365321B (enExample)
NZ (1) NZ702415A (enExample)
RU (1) RU2650962C2 (enExample)
WO (1) WO2013185105A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874850A1 (en) 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
CN106413701A (zh) * 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法
EP3277272B1 (en) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
US20210123021A1 (en) * 2018-01-26 2021-04-29 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
WO1998026781A1 (en) * 1996-12-19 1998-06-25 American Cyanamid Company Method of treating or inhibiting neutropenia
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004100972A1 (ja) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
BRPI0514343A (pt) 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
PL1841432T3 (pl) 2004-12-02 2011-01-31 Venus Remedies Ltd H O&R&D Kompozycje do zwalczania oporności antybiotykowej opartej na aktywności beta-laktamazy przy użyciu inhibitorów beta-laktamazy przeznaczonych do iniekcji
US20090111786A1 (en) 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
JP2009537540A (ja) * 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
BRPI0819887A2 (pt) * 2007-12-06 2017-05-23 Csl Ltd métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno
EP2334814A4 (en) 2008-09-05 2012-04-25 Solulink Biosciences Inc METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA INJURIES
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
AU2013259624B2 (en) * 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CA2874850A1 (en) 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN106413701A (zh) 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641091A (zh) * 2007-03-30 2010-02-03 Tmrc株式会社 他米巴罗汀胶囊剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The effects of retinoic Acid analogs on the blast cells of acute myeloblastic-leukemia in culture;Tohda S等;《Int J Oncol.》;19940630;第4卷(第6期);第1311-1314页 *
维甲酸对急性早幼粒细胞白血病白血病细胞诱导分化作用的研究;毕卫真等;《中国医科大学学报》;19911231;第20卷(第2期);第151-155页 *

Also Published As

Publication number Publication date
NZ702415A (en) 2016-04-29
JP6295249B2 (ja) 2018-03-14
JP2015523346A (ja) 2015-08-13
EP2858636A4 (en) 2016-06-01
MX2014014930A (es) 2015-07-06
BR112014030279A2 (pt) 2017-09-12
KR102083046B1 (ko) 2020-02-28
RU2650962C2 (ru) 2018-04-18
EP2858636B1 (en) 2018-09-05
RU2014153988A (ru) 2016-07-27
US20150164836A1 (en) 2015-06-18
EP2858636A1 (en) 2015-04-15
KR20150035983A (ko) 2015-04-07
CN104519879A (zh) 2015-04-15
CA2874850A1 (en) 2013-12-12
WO2013185105A1 (en) 2013-12-12
AU2013270674A1 (en) 2014-12-18
HK1208630A1 (en) 2016-03-11
AU2013270674B2 (en) 2017-12-07
ES2691493T3 (es) 2018-11-27
US11116738B2 (en) 2021-09-14
MX365321B (es) 2019-05-29

Similar Documents

Publication Publication Date Title
CN104519879B (zh) 使用类视色素激动剂治疗中性粒细胞减少症的方法
JP6695286B2 (ja) リンパ腫の処置
JP2022172262A (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
JP2021513853A (ja) 癌免疫療法のためのチェックポイント遮断としての操作されたナノベシクル
EA037117B1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
JP6353073B2 (ja) 細胞回復のための組成物並びにその作製及び使用方法
EP2978439B1 (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
JP2019503386A (ja) 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用
Tabansky et al. Advancing drug delivery systems for the treatment of multiple sclerosis
Ahmad et al. Deciphering the enigma of neuron-glial interactions in neurological disorders
CA2155920A1 (en) Use of interferon for the inhibition of proliferation and differentiation of primitive hematopoietic progenitor cells
WO2024036005A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
ES2789574T3 (es) Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor
Wang et al. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis
US20230330193A1 (en) Enhancement of stem cell therapy for cartilage degeneration by anti-oxidant pre-conditioning
CN117159525A (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
EP4578454A1 (en) Compositions comprising platelet derived extracellular vesicles
WO2025059662A1 (en) Artificial antigen presenting cells to improve t cell function
HK40077184A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
HK1215790B (en) A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
HK1226332B (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
HK1226332A1 (en) A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181002

CF01 Termination of patent right due to non-payment of annual fee